
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is a biopharmaceutical company that focuses on developing and commercializing first-in-class medicines that meet unmet medical needs. Its Tenapanor product, marketed as IBSRELA and XPHOZAH, targets patients with specific gastrointestinal disorders. Despite a recent setback in reimbursement headwinds and a change in chief commercial officer, Ardelyx remains on solid footing to execute its current plan. With a strong pipeline, potential for continued prescription data growth, and initiatives to overcome access barriers, Ardelyx's $1 billion peak net sales goal seems achievable. However, the company still faces typical industry risks, including unexpected outcomes from clinical trials and regulatory uncertainty.
Bears say
Ardelyx is facing potential challenges with its commercial execution and competition from other players in the market, leading to a topline miss and revised guidance for its flagship product, Ibsrela. In addition, while the company has strong momentum with its other product, Xphozah, market dynamics and competition may affect its long-term success. Despite potential for growth in the future, the uncertain timeline for reaching key milestones and the need for increased investment in marketing and sales activities could negatively impact the company's financials and ultimately its stock price.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares